微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 2.81% | 20.6% | 9.34% | 90/160 | 4.14% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | 2.57% | 30.46% | 91.79% | 71/160 | 2.6% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | 1.34% | 4.69% | -64.83% | 80/160 | 2.3% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | 3.81% | 14.76% | 63.52% | 73/160 | -0.96% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 2.33% | 9.91% | 18.27% | 103/160 | 2.37% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | 1.97% | 10.67% | 53.91% | 86/160 | 1.51% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 1.28% | -3.03% | -61.45% | 79/160 | 1.38% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | 3.32% | 12.16% | 56.6% | 88/160 | 0.8% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 2.12% | -48.54% | 19.1% | 96/160 | 2.89% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 1.78% | -40.47% | 34.85% | 94/160 | 2.24% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 1.32% | -32.99% | -55.41% | 78/160 | 1.61% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 2.96% | -63.05% | -28.16% | 90/160 | 0.94% | 人福医药 | 6.82% | 行业排名> |
| 2021-09-30 | 4.12% | -43.64% | 37.79% | 86/160 | 4.53% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 2.99% | -43.8% | 51.78% | 79/160 | 2.99% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 1.97% | -23.94% | -75.41% | 68/160 | 2.52% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | 8.01% | -48.39% | 9.58% | 70/160 | 3.74% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | 7.31% | -42.8% | 37.41% | 55/160 | 3.22% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | 5.32% | -37.78% | 105.41% | 51/160 | 4.24% | 河化股份 | 45.32% | 行业排名> |
| 2020-03-31 | 2.59% | -31.12% | -83.31% | 40/160 | 2.24% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | 15.52% | 3.88% | 21.44% | 31/160 | 2.78% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 12.78% | 10.27% | 49.47% | 18/160 | 7.61% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 8.55% | 15.07% | 127.39% | 22/160 | 5.05% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 3.76% | 16.41% | -74.83% | 22/160 | 2.46% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 14.94% | 16.45% | 28.9% | 33/160 | 7.09% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 11.59% | 17.78% | 55.99% | 16/160 | 7.26% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 7.43% | 18.69% | 130.03% | 20/160 | 4.65% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 3.23% | 14.95% | -74.82% | 26/160 | 2.55% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 12.83% | -27.31% | 30.39% | 33/160 | 9.66% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 9.84% | 2% | 57.19% | 32/160 | 8.31% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 6.26% | -26.87% | 122.78% | 32/160 | 5.59% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 2.81% | 2% | -84.08% | 32/160 | 2.1% | 河化股份 | 54.24% | 行业排名> |
| 2016-12-31 | 17.65% | -0.68% | 106.19% | 30/160 | 6.33% | 华东医药 | 7.2% | 行业排名> |
| 2016-06-30 | 8.56% | 2% | -51.83% | 21/160 | 3.53% | 南新制药 | 81.7% | 行业排名> |
| 2015-12-31 | 17.77% | -5.63% | -5.63% | 25/160 | 11.35% | 德展健康 | 29.5% | 行业排名> |